402-334-4773

Research Trials

If you have any questions or are interested in participating in one of our clinical trials, please jot down the trial number and contact your Nebraska Cancer Specialists medical oncologist or a member of our clinical research team at 402.334.4773, or email us at clinicaltrials@nebraskacancer.com.

Download All Current Trials

  • Cancer Type:

  • Biomarker:

  • Phase:

  • Keyword:

  • 7465-CL-202

    An Open-label, Multicenter, Multicohort, Phase 2 Study to Evaluate Enfortumab Vedotin in Subjects with Previously Treated Locally Advanced or Metastatic Malignant Solid Tumors (EV-202)

    Cancer Type: Esophageal

    Lines of Therapy: 2

    Phase: 2

    View Details on ClinicalTrials.gov

  • XL092-002 (STELLAR 002)

    Study of XL092 in Combination With Immuno-Oncology Agents in Subjects With Solid Tumors (STELLAR-002)

    Cancer Type: Renal

    Lines of Therapy: 1

    Phase: 1b

    View Details on ClinicalTrials.gov

  • KRONOS, KB-0742-1001

    A Phase 1, Open Label dose escalation/cohort expansion study of KB-0742 in patients with relapsed/refractory solid tumors or non-Hodgkin lymphoma

    Cancer Type: Solid tumor, nonHodgkin lymphoma

    View Details on ClinicalTrials.gov

  • Janssen Paloma 3, JNJ 61186372NSC3004

    A Phase 3, Open label, Randomized Study of Lazertinib with Subcutaneous Amivantamab administered via manual injection compared with IV Amivantamab or Amivantamab Subcutaneous on Body Delivery System in Patients with EGFR mutated Advanced or Metastatic NSCLC After progression on Osimertinib and Chemotherapy

    Cancer Type: Lung NSCLC

    Phase: 3

    View Details on ClinicalTrials.gov

  • Abbie ReVenG (M20-356)

    A Phase 2 Study to evaluate the efficacy and safety of Venetoclax-Obinutuzumab Retreatment in Patients with Recurring CLL

    Cancer Type: Lymphoma, Leukemia, CLL

    Phase: 2

    View Details on ClinicalTrials.gov

  • Boehringer Ingelheim Brightline-2 (1403-0011)

    A Phase 2a/2b, open label, study of BI907828 for treatment of patients with locally advanced/mets, MDM2 amplified, TP53 wild type biliary tract adenocarcinoma, pancreatic ductal adenocarcinoma, or other selected solid tumors

    Cancer Type: cholangiocarcinoma, Pancreatic, Solid tumor, Biliary Tract, Gall bladder, ampullary

    Phase: 2

    View Details on ClinicalTrials.gov

  • ArriVent FURMO-004

    A Phase 3 Study to investigate the efficacy and safety of Furmonertinib compared to Platinum based chemo as 1st line treatment for pateitns with locally advanced or metastatic NSCLC with EGFR Exon 20 insertion mutations.

    Cancer Type: Lung NSCLC

    Lines of Therapy: 1

    Phase: 3

    View Details on ClinicalTrials.gov

  • DESTINY-Breast09 (AstraZeneca)

    A Phase 3 Study of Trastuzumab Deruxtecan with or without Pertuzumab vs Taxane, Trastuzumab and Pertuzumab in Her2+, 1st line metastatic breast cancer

    Cancer Type: BREAST

    Lines of Therapy: 1

    Phase: 3

    View Details on ClinicalTrials.gov

  • BGB-16673-101

    A Phase 1, Open-Label, Dose-Escalation and -Expansion Study of the Bruton Tyrosine Kinase-Targeted Protein-Degrader BGB-16673 in Patients With B-Cell Malignancies

    Cancer Type: Heme

    Phase: 1

    View Details on ClinicalTrials.gov

  • BMS CA116001

    Phase 2 Open label Study of Farletuzumab Ecteribulin (MORab-202), vs Investigator's Choice Chemotherapy in Women with Platinum Resistant High Grade Serous Ovarian, Primary Peritoneal or Fallopian Tube Cancer

    Cancer Type: Peritoneal, Fallopian Tube, OVARIAN

    Lines of Therapy: 2, 3

    Phase: 2

    View Details on ClinicalTrials.gov